GENELUX CORPORATION Investing Cash Flow
GENELUX CORPORATION (GNLX) reported Investing Cash Flow of -$2.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- GENELUX CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $5.97M.
- GENELUX CORPORATION net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$8.54M, a 343.35% decline year-over-year.
- GENELUX CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $6.56M, a 1.65% decline year-over-year.
- GENELUX CORPORATION net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $4.72M, a 18.26% increase year-over-year.
- GENELUX CORPORATION net cash provided by (used in) investing activities for fiscal 2025 was $12.14M.
- GENELUX CORPORATION net cash provided by (used in) investing activities for fiscal 2024 was -$8.13M.
- GENELUX CORPORATION net cash provided by (used in) investing activities for fiscal 2023 was -$14.72M.
- GENELUX CORPORATION net cash provided by (used in) investing activities for fiscal 2022 was -$49.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.57M 10-Q · filed 2026-08-13 | $3.99M derived: sum of 3 quarters · filed 2026-08-13 | $8.71M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$8.54M 10-Q · filed 2026-05-07 | -$1.98M derived: sum of 2 quarters · filed 2026-05-07 | $2.75M derived: sum of 3 quarters · filed 2026-05-07 | $93.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $11.29M derived: sum of 2 quarters · filed 2026-03-19 | $8.63M derived: sum of 3 quarters · filed 2026-08-13 | $12.14M 10-K · filed 2026-03-19 |
| 2025-09-30 | $4.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.07M derived: sum of 2 quarters · filed 2026-08-13 | $5.58M 10-Q · filed 2025-11-05 | $12.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $856.00K 10-Q · filed 2026-08-13 | $7.53M derived: sum of 3 quarters · filed 2026-08-13 | $11.52M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $3.51M 10-Q · filed 2026-05-07 | $10.18M derived: sum of 2 quarters · filed 2026-05-07 | $14.18M derived: sum of 3 quarters · filed 2026-05-07 | -$2.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $10.67M derived: sum of 2 quarters · filed 2026-03-19 | -$6.44M derived: sum of 3 quarters · filed 2026-03-19 | -$8.13M 10-K · filed 2026-03-19 |
| 2024-09-30 | $3.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$13.11M derived: sum of 2 quarters · filed 2025-11-05 | -$14.80M 10-Q · filed 2025-11-05 | -$28.75M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$17.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$18.80M 10-Q · filed 2025-08-07 | -$32.74M derived: sum of 3 quarters · filed 2025-08-07 | -$33.02M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.69M 10-Q · filed 2025-05-06 | -$15.63M derived: sum of 2 quarters · filed 2025-05-06 | -$15.91M derived: sum of 3 quarters · filed 2025-05-06 | -$16.31M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$13.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$14.22M derived: sum of 2 quarters · filed 2025-03-28 | -$14.62M derived: sum of 3 quarters · filed 2025-03-28 | -$14.72M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$277.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$673.00K derived: sum of 2 quarters · filed 2024-11-14 | -$782.00K 10-Q · filed 2024-11-14 | -$782.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$505.00K 10-Q · filed 2024-08-14 | -$505.00K derived: sum of 3 quarters · filed 2024-08-14 | -$538.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$109.00K 10-Q · filed 2024-05-09 | -$109.00K derived: sum of 2 quarters · filed 2024-05-09 | -$142.00K derived: sum of 3 quarters · filed 2024-05-09 | -$143.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$33.00K derived: sum of 2 quarters · filed 2024-03-29 | -$34.00K derived: sum of 3 quarters · filed 2024-03-29 | -$49.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | -$33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$34.00K derived: sum of 2 quarters · filed 2023-11-14 | -$49.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$16.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$15.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |